No Carolina / NY / Florida
Ph: 561.316.3330

Warren Modlin Joins HOYA Vision Care As VP of Marketing

Editor: What To Know

  • Trained as an optometrist in South Africa and based in California, Warren Modlin brings more than 30 years of optical industry experience to HOYA, beginning with his 12-year tenure at CIBA VISION where he contributed to the launch of many innovative lens technologies.
  • In his role, Modlin leads professional relations and innovation strategies for North America, in addition to representing the North American market and delivering on key global initiatives alongside Research &.
  • I feel strongly that HOYA is best positioned to take advantage of the next generation of technology innovations to help ECPs and consumers achieve their maximum potential through vision performance.

Warren Modlin has joined the company as its Vice President of Technical Marketing. In his role, Modlin leads professional relations and innovation strategies for North America, in addition to representing the North American market and delivering on key global initiatives alongside Research & Development.

 

Trained as an optometrist in South Africa and based in California, Warren Modlin brings more than 30 years of optical industry experience to HOYA, beginning with his 12-year tenure at CIBA VISION where he contributed to the launch of many innovative lens technologies. He also held leadership positions at Oakley and has launched optical businesses including two consultancies and NDV Performance.

“I am excited to join a company that is equally dedicated to supporting its customers with innovative products and unparalleled service,” said Warren Modlin. “Product innovation and technical quality is the life blood of a great company. I feel strongly that HOYA is best positioned to take advantage of the next generation of technology innovations to help ECPs and consumers achieve their maximum potential through vision performance.”

“We are very happy to welcome Warren to our global team of visionaries,” said Eduardo Martins, President of HOYA Vision CareNorth America. “Our customers will no doubt benefit from the deep industry knowledge and marketing experience he brings to our company.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy